Translational anatomy of the left atrium and esophagus as relevant to the pulmonary vein antral isolation for atrial fibrillation

2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation

In the last three decades, ablation of atrial fibrillation (AF) has become an evidence-based safe and efficacious treatment for managing the most common cardiac arrhythmia. In 2007, the first joint expert consensus document was issued, guiding healthcare professionals involved in catheter or surgical AF ablation. Mounting research evidence and technological advances have resulted in a rapidly changing landscape in the field of catheter and surgical AF ablation, thus stressing the need for regularly updated versions of this partnership which were issued in 2012 and 2017. Seven years after the last consensus, an updated document was considered necessary to define a contemporary framework for selection and management of patients considered for or undergoing catheter or surgical AF ablation. This consensus is a joint effort from collaborating cardiac electrophysiology societies, namely the European Heart Rhythm Association, the Heart Rhythm Society, the Asia Pacific Heart Rhythm Society, and the Latin American Heart Rhythm Society.

Morphometry of left atrial appendage isthmus and mitral isthmus: implications for atrial fibrillation catheter ablation

BACKGROUND

Radiofrequency catheter ablation (RFA) targets the left atrial appendage isthmus (LAA isthmus) and mitral isthmus for treatment of atrial fibrillation. However, proximity of left circumflex artery (LCxA) and great cardiac vein (GCV) in the isthmuses poses fatal risks during ablation.

METHODS

This study investigated relationships of LCxA and GCV across three lines in the LAA and mitral isthmus, using 15 human cadaveric hearts. Distances between the vessels and the endocardium, myocardium, and perivascular fat thickness were measured.

RESULTS

The results showed that LCxA was mostly consistently located in lower atrial segments and GCV was in lower/upper atrial segments, with change of course mainly observed in the middle of the LAA. The LCxA was found as close as 3-5 mm from the lower border of the LAA isthmus in 80% of specimens, at a depth of 2-3 mm within the LAA isthmus, where 1 mm consisted of myocardium and the remainder was fat, which may not provide adequate protection due to the possibility of liquefaction of fat with heat application. The effective myocardial thickness was consistently 1 mm across all cases in both isthmuses. LCxA was 2 mm in second and third sections of LAA isthmus ("careful segment"). LCxA distances from left inferior pulmonary vein opening was 5 to 12 mm, occasionally dangerously close as <1 mm in 16% of cases.

CONCLUSION

This study measured LCxA and GCV in the LAA and mitral isthmus across three lines for the first time in the Indian population, aiding surgeons in RFA planning.

2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation

In the last three decades, ablation of atrial fibrillation (AF) has become an evidence-based safe and efficacious treatment for managing the most common cardiac arrhythmia. In 2007, the first joint expert consensus document was issued, guiding healthcare professionals involved in catheter or surgical AF ablation. Mounting research evidence and technological advances have resulted in a rapidly changing landscape in the field of catheter and surgical AF ablation, thus stressing the need for regularly updated versions of this partnership which were issued in 2012 and 2017. Seven years after the last consensus, an updated document was considered necessary to define a contemporary framework for selection and management of patients considered for or undergoing catheter or surgical AF ablation. This consensus is a joint effort from collaborating cardiac electrophysiology societies, namely the European Heart Rhythm Association, the Heart Rhythm Society (HRS), the Asia Pacific HRS, and the Latin American HRS.

2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation

In the last three decades, ablation of atrial fibrillation (AF) has become an evidence-based safe and efficacious treatment for managing the most common cardiac arrhythmia. In 2007, the first joint expert consensus document was issued, guiding healthcare professionals involved in catheter or surgical AF ablation. Mounting research evidence and technological advances have resulted in a rapidly changing landscape in the field of catheter and surgical AF ablation, thus stressing the need for regularly updated versions of this partnership which were issued in 2012 and 2017. Seven years after the last consensus, an updated document was considered necessary to define a contemporary framework for selection and management of patients considered for or undergoing catheter or surgical AF ablation. This consensus is a joint effort from collaborating cardiac electrophysiology societies, namely the European Heart Rhythm Association, the Heart Rhythm Society, the Asia Pacific Heart Rhythm Society, and the Latin American Heart Rhythm Society .

Comparison between High-Power Short-Duration and Conventional Ablation Strategy in Atrial Fibrillation: An Updated Meta-Analysis

High-power short-duration (HPSD) setting during radiofrequency ablation has become an attempt to improve atrial fibrillation (AF) treatment outcomes. This study ought to compare the efficacy, safety, and effectiveness between HPSD and conventional settings. PubMed, Embase, and Cochrane Library were searched. Studies that compared HPSD and conventional radiofrequency ablation settings in AF patients were included while studies performed additional ablations on nonpulmonary vein targets without clear recording were excluded. Data were pooled with random-effect model. Efficacy endpoints include first-pass pulmonary vein isolation (PVI), acute pulmonary vein (PV) reconnection, free from AF, and free from atrial tachycardia (AT) during follow-up. Safety endpoints include esophagus injury rate and major complication rate. Effectiveness endpoints include complete PVI rate, total procedure time, PVI time, and PVI radiofrequency ablation (PVI RF) time. We included 22 studies with 3867 atrial fibrillation patients in total (2393 patients received HPSD radiofrequency ablation). Perioperatively, the HPSD group showed a higher first-pass PVI rate (risk ratio, $\text{RR}=1.10$ , $P=0.0001$ ) and less acute PV reconnection rate ( $\text{RR}=0.56$ , $P=0.0004$ ) than the conventional group. During follow-up, free from AF ( $\text{RR}=1.11$ , $P=0.16$ ) or AT ( $\text{RR}=1.06$ , $P=0.24$ ) rate did not differ between HPSD and conventional groups 6-month postsurgery. However, the HPSD group showed both higher free from AF ( $\text{RR}=1.17$ , $P=0.0003$ ) and AT ( $\text{RR}=1.11$ , $P<0.0001$ ) rate than the conventional group 12-month postsurgery. The esophagus injury ( $\text{RR}=0.99$ , $P=0.98$ ) and major complications ( $\text{RR}=0.76$ , $P=0.70$ ) rates did not differ between the two groups. The HPSD group took shorter total procedure time ( $\text{MD}=-33.71$ 95% CI: -43.10 to -24.33, $P<0.00001$ ), PVI time ( $\text{MD}=-21.60$ 95% CI: -25.00 to -18.21, $P<0.00001$ ), and PVI RF time ( $\text{MD}=-13.72$ , 95% CI: -14.45 to -13.00, $P<0.00001$ ) than conventional groups while complete procedure rate did not differ between two groups ( $\text{RR}=1.00$ , $P=0.93$ ). HPSD setting during AF radiofrequency ablation has better effectiveness, efficacy, and similar safety compared with the conventional setting.

Derivation and Verification of the Relationship between Ablation Index and Baseline Impedance

Objective

To explore the quantitative adjustment of ablation index (AI) under different baseline impedance to achieve similar lesion dimensions.

Methods

(1) Keeping the AIs relatively constant, the lesion dimensions in different baseline impedances were studied. (2) According to Joule's law, Q = I²RT, keeping the current (I) unchanged, the powers corresponding to different baseline impedances can be obtained. Under different baseline impedances and corresponding powers, the swine hearts were ablated for 30 s in simulated human circumstances. The baseline impedances, the lesion dimensions, and AIs were recorded. And the derivation of empirical formula was achieved according to the AIs and baseline impedance values in similar lesions dimension. (3) Basic AI and baseline impedance (AI₀/R₀) were set as 400/120 Ω in the common AI groups and 550/120 Ω in the high AI groups, AI values in different baseline impedances were calculated using the empirical formula, and the corresponding lesion dimensions were measured to verify this formula.

Results

(1) Higher baseline impedances were related to smaller lesion dimensions at similar AIs. (2) The lesion dimensions were roughly the same after modulating the baseline impedance and power to keep the electric current relatively constant. The relationship between AI and R fitted with experimental data is AI = 1.9933R + 203.61 (r = 0.9649), and the formula derived is ΔAI = (AI₀ − 203)/R₀ × ΔR. (3) Under the guidance of the empirical formula, there was no significant difference in lesion dimensions between the standard group and the formula guiding groups when AI₀ = 400, but there was a shrinking tendence when AI > 700.

Conclusion

The lesion depths are negatively correlated with baseline impedance at a certain AI. The relationship between baseline impedance and AI is “ΔAI = (AI₀ − 203)/R₀ × ΔR”. It is verified that when the AI is not too high, the empirical formula can be used to guide the quantitative adjustment of AIs at different baseline impedance, and the lesion depths achieved are roughly the same.